Cytochrome P450-dependent arachidonic acid metabolism in human kidney. Cytochrome P450-dependent arachidonic acid metabolism in human kidney cortex from several postmortem subjects has been characterized. Using HPLC and GC/MS, four cytochrome P450-arachidonic acid metabolites were tentatively but not unequivocally identified as epoxyeicosatrienoic acid (EET), dihydroxyeicosatrienoic acid (DHT) and 19-and 20-hydroxyeicosatetraenoic acids, suggesting the involvement of two major cytochrome P450 enzymes, epoxygenase and w/w-l hydroxylases. This pattern of metabolism was similar to that found in rabbit and rat kidneys. The formation of these metabolites was dependent on the presence of NADPH and inhibited by IgG of NADPH-cytochrome P450 (c) reductase. Immunologic studies of renal cytochrome P450 epoxygenase demonstrated that antibodies prepared against human-purified hepatic cytochrorne P450 epoxygenase recognized renal enzyme protein and inhibited the enzyme activity by 92%. In contrast, control immunoglobulin did not inhibit renal cytochrome P450 epoxygenase. Antibody inhibition of renal cytochrome P450 epoxygenase demonstrated a degree of conservation of both enzyme proteins between liver and kidney. Antibodies against lauric acid who-I hydroxylases (P450w) inhibited the formation of ailw-I hydroxylase products, 19-and 20-HETEs. Identical qualitative patterns of arachidonic acid metabolites were observed in all cortical microsomes studied. Interindividual variations were observed in the cytochrome P450-dependent arachidonic acid metabolism, and the activities ranged from 0.031 to 5.027 nmol arachidonic acid converted/mg protein/30 mm, which is about a 150-fold difference. However, when the specific activities for total cytochrome P450-dependent arachidonic acid metabolism were calculated, two separate groups could be distinguished, high and low metabolizers of arachidonic acid. The range of the low metabolizer of arachidonic acid by cytochrome P450 was 0.15 to 0.23 pmol arachidonic acid convertedipmol P450/mm, as compared to the range of the high metabolizer which was 1.38 to 1.93 pmol arachidonic acid converted/pmol P450/mm. The interindividual variation observed with respect to arachidonic acid metabolism was also observed in other cytochrome P450 monooxygenase systems studied, aryl hydrocarbon hydroxylase and 7-ethoxyresorufin-O-deethylase. Arachidonate metabolites derived by cytochrome P450 have been shown to possess a wide range of biological activities; these include stimulation of peptide hormone release, inhibition and stimulation of NaKtATPase, vasoreactivity and mobilization of Ca. We suggest that the interindividual variations observed in cytochrome P450-dependent arachidonic acid metabolism may play a role in the susceptibility of certain individuals to develop clinical disorders such as essential hypertension.
the third pathway by which arachidonic acid (AA) can be metabolized. In the presence of NADPH and molecular oxygen [1] , the cytochrome P450 system oxidized AA by three types of reactions: 1) allylic oxidation leading to the formation of monohydroxyeicosatetranoic acids (HETEs); 2) olefin epoxidation leading to the formation of the four regioisomeric epoxyeicosatrienoic acids (EETs), which can undergo hydrolysis by epoxide hydrolase to form the corresponding diol metabolites (DHTs); 3) oxidation at wand co-i positions to form the 20-and 19-HETEs, respectively [2] [3] [4] . The highest concentration of cytochrome P450 isozymes in mammalian tissues is found in liver. However, several extrahepatic tissues contain significant levels of cytochrome P450; among them the kidney displays the highest concentration [5] [6] [7] . Cytochrome P450-dependent metabolism of endogenous substrates such as steroids, fatty acids, including AA, and prostaglandins in renal tissues may contribute to kidney function. Cortical and outer medullary microsomes, isolated proximal tubule cells and isolated cells from the thick ascending limb of Henle's loop from rabbit kidney have been shown to metabollize AA by cytochrome P450 enzymes [8] . The cytochrome P450-dependent metabolism of AA in renal preparations from rabbit and rat kidneys includes formation of EETs and their hydrolytic metabolites DHTs, and the co/co-i hydroxylated compounds -19-HETE and 20-HETE [9] . Some of these metabolites are biologically active. The 5,6-EET is a vasodilator [10] and an inhibitor of ion transport in the collecting tubules of rabbit kidney [11] . 11, 12-EET and its hydrolytic metabolite 11, 12-DHT inhibit AVP-stimulated water transport and adenylate cyclase in toad bladder [12] . The ll,12-DHT is a NatKATPase inhibitor [13] and the 19(S)-HETE is a Na-K-ATPase stimulator [14] . Furthermore, the 20-HETE produced by the kidney is a potent vasoconstrictor [15] . These biological properties implicate these metabolites in regulation of various renal functions.
Cytochrome P450 exists in multiple forms which participate in detoxification of various drugs. The different isozymes of cytochrome P450 are characterized by their substrate and product positional specificities and stereoselectivities. Their qualitative and quantitative proportions in a given tissue vary largely as a function of various physiological, pharmacological and pathological conditions [16] . Polymorphism in the oxidative metabolism of various drugs is a well known phenomenon in humans [17, 18] . Environment, diet, age, disease and, most importantly, genetic factors contribute to this polymorphism.
The metabolism of AA via cytochrome P450 in humans may be similarly polymorphic [19, 20] . There is no information available on cytochrome P450-dependent AA metabolism in human kidney.
The aims of this study were: I) to characterize the cytochrome P450-dependent AA metabolism in human kidney using antibodies against cytochrome P450 AA epoxygenase and co/w-1 hydroxylase in human renal microsomal preparation and compare it to other species such as rat and rabbit; 2) to determine the quantitative or qualitative interindividual variations in cortical cytochrome P450 AA metabolites; 3) to determine whether the interindividual variation seen with AA also exists in other monooxygenases in human kidney. (five car accidents and one cerebral hemorrhage). The renal cortex was separated, placed in ice-cold 0.15 M KCI and homogenized (4 ml/g wet wt) in 10 mrs Tris buffer, pH 7.5, containing 0.25 M sucrose. The tissue homogenates were centrifuged at 27,000 g for 20 minutes at 4°C. The supernatant was centrifuged at 105,000 g for one hour at 4°C and the resulting microsomal pellet was resuspended in 0.1 M potassium phosphate buffer, pH 7.6, and used for determination of cytochrome P450 content and monooxygenase activities such as: aryl hydrocarbon hydroxylase, 7-ethoxyresorufin-O-deethylase, AA epoxygenase and oIw-1 arachidonate hydroxylases. Protein concentration was determined by the method of Lowry Ct a! [23] with bovine serum albumin (Fraction V) as a standard.
Cytochrome P450 content and activities Cytochrome P450 content was measured from the reduced carbon monoxide difference spectrum using sodium dithionite as the reducing agent [24] . The absorbance difference between 450 and 490 was used to calculate the cytochrome P450 content, a molar absorption coefficient of 91 mM' cm' being used.
Aryl hydrocarbon hydroxylase activity was determined, using benzo(a)pyrene as the substrate following the method of Nebert and Gelboin [25] as modified in our laboratory [26] The procedure used for the purification of human liver cytochrome P450 AA epoxygenase was as previously described by our laboratory [29] . Control antibody was purified in an identical manner using sera from nonimmunized rabbits. The final protein concentration of the antibody preparation was 6 mg/ml.
Immunotitration of human kidney cytochrome P450 epoxy genase Immunotitration of cytochrome P450 epoxygenase was similar to that described previously [30] . Briefly, serial dilution of preimmune and immune purified rabbit sera were prepared in 0.9% sodium chloride containing 0.02 M potassium phosphate buffer, pH 8.0, in a final volume of 400 l. Each tube then received 400 l of enzyme containing preparation to be titrated. The mixture was incubated for 25 minutes at 25°C with various amounts of rabbit anti-human IgG of cytochrome P450 epoxygenase. After centrifugation at 15,000 x g for 20 minutes, the supernatant fractions were assayed for AA metabolism as described above. In the control, the enzyme activity did not change significantly during the pre-incubation period, and the pre-immune serum did not precipitate detectable quantities of cytochrome P450 epoxygenase. We found that the level of inhibition of cytochrome P450 epoxygenase was achieved when the ratio of antibodies to microsomal protein was 1:3.
Results
Arachidonic acid metabolism by renal microsomes via cytochrome P450-dependent monooxygenase Metabolites of AA formed by cytochrome P450-dependent enzyme(s) were defined as those metabolites whose formation was absolutely dependent on NADPH addition, inhibited by SKF-525A, an inhibitor of cytochrome P450-dependent enzymes via a type-I binding mechanism [31] , or inhibited by antibodies to cytochrome P450 (c) reductase [30] , the essential component of the electron transport cytochrome P450 monooxygenase system. The various metabolites were separated by HPLC. Table 1 shows the retention times of various synthetic standards of cytochrome P450-AA metabolites on reverse phase HPLC. In the absence of NADPH, the conversion of 14C..AA was very low (3 to 5% of total radioactivity) and accounted for mainly by cyclooxygenase metabolites. In the presence of NADPH, AA was converted into cytochrome P450-derived metabolites by all human renal microsomal preparations studied. The formation of these metabolites was inhibited by SKF-525A (100 MM), an inhibitor of cytochrome P450-dependent enzyme, but was not affected by indomethacin (10 t.M) a cyclooxygenase inhibitor indicating that they are derived by the cytochrome P450 pathway (data not shown). Figures lA and lB represent HPLC separation of AA metabolites formed by cortical microsomes of subjects 4 and 5, respectively, in the presence of NADPH. Three major radioactive peaks were separated: peaks I, II and III. Peak I was eluted between 14 and 16 minutes and corresponded to the DHT metabolites (Table I) relatively large amounts of peaks I, II and III (2 to 5 g) and determined the structure of metabolites by gas chromatography/mass spectometry (GC/MS).
The mass spectra of the methylester trimethylsilyl derivative of peak II showed the presence of two metabolites, ha and II b, The comigration of these metabolites on an HPLC with standard compounds and the GC/MS data are consistent with the structure of these metabolites and clearly reveal the presence of at least two types of oxidative pathways represented by two or more isozymes. The first type was catalyzed by cytochrome P450 epoxygenase activity which is represented by the formation of epoxides, mainly 11, 12-EET (peak III) and their hydrolytic metabolites DHT, mainly 11, l2-DHT (peak I). The second type of oxidative pathway is catalyzed by os'cu-1 hydroxylases which are represented by the formation of 19-HETE and 20-HETE (peak II). To distinguish between the oxidative pathways of AA by cytochrome P450, we carried out the following series of experiments: human cortical microsomes were incubated with antibodies prepared against the purified human liver cytochrome P450 epoxygenase. The formation of cytochrome P450 AA metabolites ( Fig. 2A) which was dependent on NADPH addition (Fig. 2C) , was inhibited by IgG to human liver cytochrome P450 AA epoxygenase (Fig. 2B) . As seen in Figure 2B , formation of peak III (mainly 11, 12-EET) was inhibited by 90%, whereas the formation of peaks I (mainly 11 ,12-DHT) and II (19-and 20-HETEs) was inhibited by 50% and 40%, respectively. Peak II, which is a product of o/w-1 hydroxylase, was inhibited by 40% when microsomes were incubated with IgG of lauric acid w/o-l hydroxylase (P450). The formation of AA metabolites via w/w 1 hydroxylase as well as via AA epoxygenase was prevented by antibodies to cytochrome P450 (c)
reductase, an integral component of all cytochrome P450 monooxygenase systems, whereas the pre-immune IgG had no effect (data not shown). A summary of the P450 contents and specific activities of the two AA oxidative pathways as well as other cytochrome P450 monooxygenases present in renal microsomes from six subjects is represented on Table 2. Note that large variations (40-to 100-fold) exist between individual subjects for the activities of coloj-1 hydroxylase and epoxygenase, respectively. Furthermore, determinations of specific activities revealed a group of subjects with low specific activity, 0.15 to 0.23 pmol AA/ minlpmol cytochrome P450 (subjects number 1,2,6) and a group with high specific activity, 1.38 to 1.93 pmol AA/min/pmol cytochrome P450 (subjects number 3,4,5).
The cytochrome P450 content and its dependent monooxygenase activities, aryl hydrocarbon hydroxylase and 7-ethoxyresorufin-O-deethylase, were also measured in renal cortical microsomes. As seen in Table 2 , cytochrome P450 was present in spectrally detectable amounts in human cortical microsomes, although the basal levels varied dramatically in individuals examined. These variations were also observed in the activities of the cytochrome P450 monooxygenase system. Renal microsomes from subject 3 possessed aryl hydrocarbon hydroxylase activities of 998 as compared to 9.6 pmol 3-OH benzo(a)pyrene/ mg/mm in subject 6. Similar observations in benzo(a)pyrene metabolism can be seen between other subjects with a variation of a 25-to 100-fold difference. The level of aryl hydrocarbon hydroxylase activities did not follow the amount of cytochrome P450 level. Thus, although renal cortex from subject 6 showed the lowest aryl hydrocarbon hydroxylase activity, its cytochrome P450 content was not the lowest level observed (Table 2) .
The activity of 7-ethoxyresorufin-O-deethylase was also compared among the six subjects. We observed a similar individual variation in the levels of 7-ethoxyresorufin-O-deethylase; the largest differences were observed between subjects number 3 and 5.
Discussion
In this paper, we demonstrated that human kidney metabolized AA by two types of oxidative pathways, epoxygenase and wko-1 hydroxylase. Formation of AA metabolites by human kidney cytochrome P450 was dependent on the presence of NADPH and inhibited by antibodies against cytochrome P450 (c) reductase. These metabolites resembled those described in rabbit and rat kidney [9, 32] . In this investigation, we have used antibodies against human liver cytochrome P450 AA epoxygenase to characterize human kidney cytochrome P450 epoxygenase. Antibodies raised against human liver cytochrome P450 AA epoxygenase inhibited the formation mainly of peak III (EETs) of renal cytochrome P450 metabolism of AA.
Although we observed identical qualitative patterns of AA metabolites by human cortical cytochrome P450 from different subjects, there were large quantitative differences in total Renal cortical microsomes from six individuals were prepared and the cytochrome P450 content, AA-epoxygenase (formation of EET + DHT, peaks III and I), AA-hydroxylase (formation of peak II), aryl hydrocarbon hydroxylase and 7-ethoxyresorufin-O-deethylase were measured as described in Methods. The results are the mean of two determinants. cytochrome P450 AA metabolism. Thus, there are individuals in which the specific activity of the cytochrome P450-dependent AA metabolizing isozymes is higher than others by a factor of 100. The presence of these isozymes may contribute to the capacity of the individual to metabolize AA. As seen in Table 2 there are low and high metabolizers of AA to the epoxides and w/u 1 hydroxylated compounds. Part of the quantitative differences may be due to variation in postmortem time. Indeed, in experiments with rat and rabbits in which we measured renal cytochrome P450 content and its activities including AA metabolism at different postmortem times (5 to 12 hr), we observed gradual reduction up to 50% by 12 hours. Thus, a one-to twofold difference may account for autolysis followed by different postmortem time. However, a 50-to 100-fold difference observed in cytochrome P450 AA metabolism is a reflection of intraindividual variation previously reported for other cytochrome P450 enzymes in human liver [17] [18] [19] .
In addition, we recently obtained biopsies of human kidney cortex from patients with hypernephroma. The tissues were placed in liquid nitrogen immediately upon surgery. The P450 content and its activities including AA metabolism in microsomal preparations were measured. The values obtained in normal kidney cortex biopsies for these activities were in similar ranges to that in the postmortem tissues, that is, between 8.0 and 104.4 pmol AA/mg/min.
Previous work from our laboratory, as well as others, has shown that epoxides derived from epoxygenase activity are potent secretagogues, vasodilators, and inhibitors of ion transport mechanisms [10] [11] [12] [13] 33] . We also demonstrated that the formation of 19-and 20-HETE is increased during the development of hypertension in spontaneously hypertensive rats, suggesting their involvement in the elevation of blood pressure [34] . We recently demonstrated the ability of 19(S)HETE to stimulate Na-K-ATPase at physiological concentrations [14] . This biological property of 19(S)HETE is compatible with the sodium retention which occurs in the early stage of blood pressure elevation in the spontaneously hypertensive rats [34] . Furthermore, 20-HETE is a potent vasoconstrictor [15] and may affect renal vascular resistance and contribute to the pathogenesis of hypertension. Thus by manipulating Na4-K4-ATPase activity, dilating and/or constricting vascular smooth muscles, these metabolites may influence renal function and contribute to the development of a pathological state such as hypertension.
It is interesting to note that the kidney of subject 3 came from a 42-year-old male who had died from cerebral hemorrhage, a possible manifestation of untreated essential hypertension. This kidney demonstrated the highest activity of both wlw-1 hydroxylase and epoxygenase. A large number of individuals grouped for age and sex as well as for normal and hypertensive states would have to be screened for the level of P450-AA enzymes before an association between these isozyme activities and hypertension can be established.
